Le Lézard

Communiqués de presse par sujet : Essais cliniques / Découvertes médicales

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

3 octobre 2017

05:30
VANCOUVER, British Columbia, and MENLO PARK, Calif., Oct. 3, 2017 /PRNewswire/ -- DelMar Pharmaceuticals (Nasdaq: DMPI) ("DelMar" and "the Company"), a biopharmaceutical company focused on the development of new cancer therapies, today announced the...

02:00
Preliminary data from ASPIRO, the ongoing Phase 1/2 Clinical Study of AT132, expected in fourth quarter of 2017 SAN FRANCISCO, Oct. 3, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing...


2 octobre 2017

23:19
CAPE CANAVERAL, Fla., Oct. 2, 2017 /PRNewswire/ -- A recent peer-reviewed study published in Frontiers in Neurology: Neurotrauma Section (Impact Factor 3.552) showing "statistical and substantive significant decreases in Post Concussive Syndrome...

22:19
BASEL, Switzerland, Oct. 2, 2017 /PRNewswire/ -- Myovant Sciences (NYSE: MYOV) today announced that Takeda Pharmaceutical Company Limited ("Takeda") has reported positive top-line results from a Phase 3 study evaluating the efficacy and safety of...

16:50
ATLANTA, Oct. 2, 2017 /PRNewswire/ -- Today the Sterling Institutional Review Board (Sterling IRB) announced its establishment of a new North American Panel to expand Sterling's program of ethical oversight for human subjects research.  "While...

15:38
BOSTON, Oct. 2, 2017 /PRNewswire/ -- CSA Medical announced today that the first patient treatment using the new Rapid AV Spray Catheter was completed at the University of Rochester Medical Center by Dr. Vivek Kaul for the management of persistent...

14:58
BIRMINGHAM, Ala., Oct. 2, 2017 /PRNewswire-USNewswire/ -- Southern Research and Bionetix Inc., a South Korea-based biotech firm, have signed a research and license agreement to develop a new anti-cancer drug that affects a key genetic switch...

13:29
KFAR SABA, Israel, October 2, 2017 /PRNewswire/ -- In the news release, "CartiHeal Performs the First 16 Cases in the Agili-Ctm Implant IDE Multinational Pivotal Study" issued on 2 Oct 2017 12:07 GMT, by CartiHeal over PR Newswire, we are advised by...

12:37
MOUNT OLIVE, N.J., Oct. 2, 2017 /PRNewswire/ -- Flowonix Medical, Inc. and Cerebral Therapeutics, Inc. announced today the successful implant of the fifth patient in the ADDRESS (Australian Direct Drug Administration for Refractory Epilepsy) trial. ...

12:32
KFAR SABA, Israel, Oct. 2nd, 2017 /PRNewswire/ -- CathWorks Ltd., a leader in the development of non-invasive FFR measurements for guiding coronary interventions, today announced the completion of a  $15.8M Series B round of financing, led by Quark...

12:16
RARITAN, N.J., Oct. 2, 2017 /PRNewswire/ -- Ortho Clinical Diagnostics (Ortho), a global leader of in vitro diagnostics, today announced it will present new scientific research on automation in immunohematology, or pre-transfusion compatibility...

12:06
NEW YORK, Oct. 2, 2017 /PRNewswire-USNewswire/ -- People with multiple sclerosis (MS) who underwent a non-invasive form of electrical brain stimulation experienced significant reductions in fatigue, a common and often debilitating symptom of the...

11:38
REUTLINGEN, Allemagne et SAINT-DENIS France, October 2, 2017 /PRNewswire/ -- L'autorité française de la santé HAS a approuvé la demande de « Forfait innovation » de Retina Implant AG LaHaute Autorité de Santé vient d'approuver la demande de «...

11:00
REDWOOD CITY, Calif., Oct. 2, 2017 /PRNewswire/ -- Oncologists may get a new tool for identifying which of their cancer patients are most likely to respond to widely prescribed immunotherapies, recent research suggests. In a paper published in...

09:15
WASHINGTON, Oct. 2, 2017 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VANDA) (NASDAQ: VNDA) today announced that data from the results of the Phase II study of tradipitant in atopic dermatitis will be presented at the 9th World Congress of Itch in...

09:00
BOSTON, October 2, 2017 /PRNewswire/ -- Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing therapeutics to treat mitochondrial dysfunction, today announced that the U.S. Food and Drug Administration's (FDA)...

08:30
KFAR MALAL, Israel, October 2, 2017 /PRNewswire/ -- Medial EarlySign (http://www.earlysign.com ), a developer of machine learning tools for data-driven medicine, today announced the results of new research in collaboration with a top integrated...

08:10
KFAR SABA, Israël, October 2, 2017 /PRNewswire/ -- CartiHeal, le développeur d'Agili-C, un implant exclusif destiné au traitement des lésions de la surface articulaire, a annoncé aujourd'hui le début de son étude de clinique de demande d'exemption...

08:03
KFAR SABA, Israel, October 2, 2017 /PRNewswire/ -- CartiHeal, developer of Agili-C, proprietary implants for the treatment of joint surface lesions, announced today the initiation of Its IDE clinical study. 16 patients were enrolled and operated on...

08:00
MALVERN, Pennsylvania, Oct. 2, 2017 /PRNewswire/ -- Essential Medical today announced the completion of enrollment in the US pivotal IDE trial of the MANTAtm large bore vascular closure device.   "Our team is thrilled...

08:00
DUBLIN, Oct. 2, 2017 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for AVYCAZ® (ceftazidime and...

08:00
PALO ALTO, Calif., Oct. 2, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced that two abstracts will be presented at the American Association for the Study of Liver Diseases (AASLD) meeting in Washington DC, October...

08:00
SAN DIEGO and VANCOUVER, British Columbia, Oct. 2, 2017 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris") today provided an update on clinical trial enrollment of its Phase 2b study of topsalysin as a treatment for...

07:35
Initiation of a Phase 1/2 Combination Clinical Trial with Galinpepimut-S and KEYTRUDA® (pembrolizumab) Across Various Indications Expected in 1H, 2018 HAMILTON, Bermuda and NEW YORK, Oct. 2, 2017 /PRNewswire/ -- SELLAS Life Sciences Group, Ltd....

07:00
TARRYTOWN, N.Y., Oct. 2, 2017 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced two new collaborations with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary...

07:00
TEL AVIV, Israel, October 2, 2017 /PRNewswire/ -- Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV, TASE: KTOV), an innovative biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) filed the Company's New Drug...

07:00
SOUTH SAN FRANCISCO, Calif., Oct. 2, 2017 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) and Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) today announced a collaboration to explore development of a novel approach to the prevention of opioid...

06:30
NEW HAVEN, Conn., Oct. 2, 2017 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today reported topline results from its Phase 2/3 clinical trial evaluating trigriluzole compared to placebo for the treatment of patients with...

02:19
UPPSALA, Sweden, Oct. 2, 2017 /PRNewswire/ -- Orexo AB (publ.) today announced that Orexo has signed an asset purchase agreement with Gesynta Pharma AB ? a recently formed research company located in Stockholm, Sweden. Among the founders are highly...

01:00
LEIDEN, The Netherlands, October 2, 2017 /PRNewswire/ -- RUCONEST® provided clinically meaningful relief of symptoms in children with hereditary angioedema  Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM) announced...


29 septembre 2017

14:24
LEIDEN, the Netherlands, September 29, 2017 /PRNewswire/ -- RUCONEST® provided clinically meaningful relief of symptoms in children with hereditary angioedema  Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM)...

07:30
SHELTON, Conn., Sept. 29, 2017 /PRNewswire/ -- NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), reports that it has filed its financial year end annual report (Form 10-K) with the Securities and Exchange Commission (SEC) on Thursday,...

04:27
LUND, Sweden, September 29, 2017 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced the company's Marketing Authorization Application (MAA) for the investigational, weekly and monthly CAM2038 buprenorphine depots for the treatment of opioid...

02:00
Les résultats à un an de plus de 100 patients dans 9 hôpitaux répartis dans 4 pays européens démontrent que l'iFuse Implanttm est sûr et plus efficace que les soins conservateurs SAN JOSE, Californie, le 29 septembre 2017 /PRNewswire/ -- SI-BONE,...


28 septembre 2017

16:30
Safety Review Committee Reports Encouraging Drug Distribution and Tolerability TORONTO and HOUSTON, Sept. 28, 2017 /CNW/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA), a clinical stage immuno-oncology company, announced...

15:11
SAN DIEGO, Sept. 28, 2017 /PRNewswire/ -- ViaCyte, Inc., a privately-held regenerative medicine company, today announced that the California Institute for Regenerative Medicine (CIRM) approved a grant of $20 million to support the clinical...

14:00
LOS ANGELES, Sept. 28, 2017 /PRNewswire/ -- Med-X, Inc. (Med-X) With all regulatory matters resolved in its favor, Med-X, Inc. is pleased to announce a return to Regulation A+ equity crowdfunding via the StartEngine platform. Med-X's offering was...

11:02
OSAKA, Japan and FLORHAM PARK, N.J., Sept. 28, 2017 /PRNewswire/ -- Shionogi & Co., Ltd. (hereafter "Shionogi") today announced it will share the latest data on cefiderocol (S-649266), an investigational siderophore cephalosporin with a novel...

10:00
JERSEY CITY, N.J., Sept. 28, 2017 /PRNewswire/ -- TrialScope, the global leader in clinical trial transparency and compliance solutions, announced new findings from its sponsor survey on clinical trial results sharing practices, at CBI's second...

09:00
SANTA CLARA, California and WASHINGTON, September 28, 2017 /PRNewswire/ -- Acceliant, the global leader in e-clinical data management solutions, has partnered with Turacoz, a leading medical communications company that provides customized,...

08:00
PALO ALTO, Calif., Sept. 28, 2017 /PRNewswire/ -- Eidos Therapeutics, a subsidiary of BridgeBio Pharma, today announced dosing of the first healthy adult cohort in the first-in-human, Phase 1 clinical trial of AG10 (NCT03294707). Eidos is developing...


27 septembre 2017

16:54
FORT WASHINGTON, Pa., Sept. 27, 2017 /PRNewswire-USNewswire/ -- Historically, randomized controlled trials have served as the state-of-the-art method for determining the efficacy and safety of new, innovative treatment regimens for patients with...

16:48
SAN DIEGO, Sept. 27, 2017 /PRNewswire/ -- Genelux Corporation, a privately-held biopharmaceutical company focused on the development of its proprietary oncolytic immunotherapy platform, today announced that it has treated the first patient in a Phase...

14:30
PRINCETON, N.J., Sept. 27, 2017 /PRNewswire/ -- Braeburn Pharmaceuticals, Inc. (Braeburn) today participated in the Third Meeting of the President's Commission on Combating Drug Addiction and the Opioid Crisis held in the Eisenhower Executive...

10:48
CAESAREA, Israel and NEW YORK, Sept. 27, 2017 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today announced that its MyDario product is expected to appear on The...

09:00
REDWOOD SHORES, Calif., Sept. 27, 2017 /PRNewswire/ -- PROCEPT BioRobotics, a Silicon Valley robotics company developing intelligent surgical solutions to treat prostate disease, has announced that the first patients have been treated in the WATER II...

08:45
DENVER, Sept. 27, 2017 /PRNewswire/ -- The Colorado Center for Reproductive Medicine (CCRM), a leading fertility treatment network, is conducting a clinical research study to explore how its natural antioxidant supplement, GameteHealth, could...

08:30
TEL AVIV, Israel, Sept. 27, 2017 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX) ("Therapix" or the "Company"), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based drugs, today announced new...

08:30
PARSIPPANY, N.J., Sept. 27, 2017 /PRNewswire/ -- Castle Creek Pharmaceuticals (CCP), a global company dedicated to delivering transformative therapies to patients with orphan dermatologic and other underserved conditions, today announced the...

07:36
SAN DIEGO, Sept. 27, 2017 /PRNewswire/ -- Agena Bioscience today announced a comparative study published in PLOS ONE highlighting the use of its mass spectrometry-based platform and new, highly sensitive iPLEX® HS chemistry for detection of somatic...

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15